Nuclear pore protein POM121 regulates subcellular localization and transcriptional activity of PPARγ

• Published in: Cell death & disease Vol. 15; no. 1; p. 7
• Main Authors: Yu, Yanxiong, Farooq, Mohammad S, Eberhart Meessen, Sabine, Jiang, Yidan, Kato, Dominik, Zhan, Tianzuo, Weiss, Christel, Seger, Rony, Kang, Wei, Zhang, Xiang, Yu, Jun, Ebert, Matthias P A, Burgermeister, Elke
• Format: Journal Article
• Language: English
• Published: England Springer Nature B.V 04.01.2024; Nature Publishing Group
• Subjects: Cell cycle; Cell proliferation; Chromosome 7; Colorectal carcinoma; CRISPR; Cytosol; Diabetes mellitus; Extracellular signal-regulated kinase; Humans; Lipid metabolism; Localization; Membrane Glycoproteins - metabolism; Metabolic disorders; Metabolism; Neoplasms - metabolism; Nuclear Pore - metabolism; Nuclear Pore Complex Proteins - metabolism; Nuclear pores; Peroxisome proliferator-activated receptors; PPAR gamma - genetics; PPAR gamma - metabolism; Raf protein; RNA, Guide, CRISPR-Cas Systems; Signal transduction; siRNA; Transcription factors; Transcription Factors - metabolism; Tumors
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-023-06371-1

Manipulation of the subcellular localization of transcription factors by preventing their shuttling via the nuclear pore complex (NPC) emerges as a novel therapeutic strategy against cancer. One transmembrane component of the NPC is POM121, encoded by a tandem gene locus POM121A/C on chromosome 7. Overexpression of POM121 is associated with metabolic diseases (e.g., diabetes) and unfavorable clinical outcome in patients with colorectal cancer (CRC). Peroxisome proliferator-activated receptor-gamma (PPARγ) is a transcription factor with anti-diabetic and anti-tumoral efficacy. It is inhibited by export from the nucleus to the cytosol via the RAS-RAF-MEK1/2-ERK1/2 signaling pathway, a major oncogenic driver of CRC. We therefore hypothesized that POM121 participates in the transport of PPARγ across the NPC to regulate its transcriptional activity on genes involved in metabolic and tumor control. We found that POM121A/C mRNA was enriched and POM121 protein co-expressed with PPARγ in tissues from CRC patients conferring poor prognosis. Its interactome was predicted to include proteins responsible for tumor metabolism and immunity, and in-silico modeling provided insights into potential 3D structures of POM121. A peptide region downstream of the nuclear localization sequence (NLS) of POM121 was identified as a cytoplasmic interactor of PPARγ. POM121 positivity correlated with the cytoplasmic localization of PPARγ in patients with KRAS mutant CRC. In contrast, POM121A/C silencing by CRISPR/Cas9 sgRNA or siRNA enforced nuclear accumulation of PPARγ and activated PPARγ target genes promoting lipid metabolism and cell cycle arrest resulting in reduced proliferation of human CRC cells. Our data suggest the POM121-PPARγ axis as a potential drugable target in CRC.